{"id":810464,"date":"2025-02-07T08:27:53","date_gmt":"2025-02-07T13:27:53","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/"},"modified":"2025-02-07T08:27:53","modified_gmt":"2025-02-07T13:27:53","slug":"ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/","title":{"rendered":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">ROCKVILLE, Md. and SUZHOU, China, Feb.  07, 2025  (GLOBE NEWSWIRE) &#8212; Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the \u201cOffering\u201d) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (\u201cADSs\u201d) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering expenses payable by Ascentage Pharma. The closing of the over-allotment option is subject to customary closing conditions.<\/p>\n<p>J.P. Morgan and Citigroup acted as joint book-running managers for the offering.<\/p>\n<p>\n        <strong>About Ascentage Pharma<\/strong>\n      <\/p>\n<p>Ascentage Pharma is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in hematological malignancies. Ascentage Pharma has been listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code 6855.HK since October 2019 and has also been listed on the Nasdaq Global Market under the ticker symbol \u201cAAPG\u201d since January 2025.<\/p>\n<p>\n        <strong>Contacts<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations<\/strong>\n      <\/p>\n<p>Hogan Wan, Head of IR and Strategy<br \/>Ascentage Pharma<br \/>Hogan.Wan@ascentage.com<br \/>+86 512 85557777<\/p>\n<p>Stephanie Carrington<br \/>ICR Healthcare<br \/>Stephanie.Carrington@icrhealthcare.com<br \/>(646) 277-1282\u00a0<\/p>\n<p>\n        <strong>Media Relations<\/strong>\n      <\/p>\n<p>Sean Leous<br \/>ICR Healthcare<br \/>Sean.Leous@icrhealthcare.com<br \/>(646) 866-4012<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ODc1ZjVhNmEtM2NlNy00ZmEyLWJmOWUtNDg5MjU3ODVjZDdiLTEzMDcyMzE=\/tiny\/ASCENTAGE-PHARMA-GROUP-INTERNA.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the \u201cOffering\u201d) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (\u201cADSs\u201d) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-810464","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the \u201cOffering\u201d) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (\u201cADSs\u201d) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering &hellip; Continue reading &quot;Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-07T13:27:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares\",\"datePublished\":\"2025-02-07T13:27:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/\"},\"wordCount\":257,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/\",\"name\":\"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\",\"datePublished\":\"2025-02-07T13:27:53+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/","og_locale":"en_US","og_type":"article","og_title":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk","og_description":"ROCKVILLE, Md. and SUZHOU, China, Feb. 07, 2025 (GLOBE NEWSWIRE) &#8212; Ascentage Pharma (Nasdaq: AAPG, HKEX: 6855) announced today that the underwriters of its underwritten U.S. initial public offering (the \u201cOffering\u201d) have partially exercised their over-allotment option to purchase an additional 935,144 American depositary shares (\u201cADSs\u201d) at the initial public offering price of $17.25 per ADS less underwriting discounts and commissions. Each ADS represents four ordinary shares of Ascentage Pharma. After giving effect to the partial exercise of the over-allotment option, the total number of ADSs sold by Ascentage Pharma in the Offering will increase to 8,260,144 ADSs and the aggregate gross proceeds to Ascentage Pharma will be approximately $142.5 million, before deducting underwriting discounts and commissions and other offering &hellip; Continue reading \"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-07T13:27:53+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares","datePublished":"2025-02-07T13:27:53+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/"},"wordCount":257,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/","name":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=","datePublished":"2025-02-07T13:27:53+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTM1NDkzNiM2NzQxMTIwIzIyOTU2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ascentage-pharma-announces-partial-exercise-of-underwriters-option-to-purchase-additional-american-depositary-shares\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ascentage Pharma Announces Partial Exercise of Underwriters\u2019 Option to Purchase Additional American Depositary Shares"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810464","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=810464"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/810464\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=810464"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=810464"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=810464"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}